NCE-1 Intelligence & Market Opportunity

Exblifep

Cefepime And Enmetazobactam

Antibiotic

IV Powder

Exblifep is an antibiotic drug used in adults to treat complicated urinary tract infections, such as kidney infections, hospital-acquired pneumonia, including ventilator-associated pneumonia, and bacteraemia when associated or suspected to be associated with these infections.

Approval Date

22-Feb-24

NCE-1 Date

22-Feb-28

NCE Date

22-Feb-29

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Cefepime And Enmetazobactam

Innovator

ALLECRA THERAPEUTICS SAS

Dosage Form

IV Powder

Strength

EQ 2 gm base/vial; 0.5 gm/vial

Therapeutic Category

Antibiotic

Usage

To treat complicated urinary tract infections

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.